The clinical development of aurora kinase inhibitors in acute myeloid leukemia

Kevin R. Kelly, Ciara L. Freeman, Francis J. Giles*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition in the treatment of acute myeloid leukemia (AML). Moreover, early-phase clinical studies on AML have shown that these agents have therapeutic efficacy both alone and in combination with chemotherapy.

Original languageEnglish (US)
Title of host publicationTargeted Therapy of Acute Myeloid Leukemi
PublisherSpringer New York
Pages391-407
Number of pages17
ISBN (Electronic)9781493913930
ISBN (Print)9781493913923
DOIs
StatePublished - Jan 1 2015

Keywords

  • Acute myeloid leukemia
  • Aurora kinases

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'The clinical development of aurora kinase inhibitors in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this